Short regimen for preventing TB found safe when co-administered with new first-line HIV drug

In an important moment for tuberculosis (TB) control, a new study finds that a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat Human Immuno-deficiency Virus (HIV) in many high-burden TB countries. Presented